Novel Targets for Alzheimer’s Disease Treatment: Medin and PLD3
Nina Culum2023-03-27T14:52:16-04:00News, Scientific Articles|
Given that Alzheimer's disease is multifactorial and heterogenous, drug development progress is more likely to occur if multiple pathways are considered. Two recent Nature publications have potentially identified medin and PLD3 as new targets for Alzheimer’s disease treatment, which we summarize in this mini-review.
Featured Webinars
A Ready-to-Analyze High-Plex Spatial Signature Development Workflow for Cancer Immunotherapy
Tuesday, November 28, 2023
Sponsors: Akoya Biosciences, OracleBio
Partner: Scientist.com
More Than What You Eat: The Regulation of Metabolic Health and Aging by Diet Composition and Activity
Tuesday, November 28, 2023
Sponsor: Columbus Instruments
Advancing Disease Modeling for Drug Discovery by Modulating iPSCs with CRISPR and Neuronal Differentiation
Wednesday, November 29, 2023
Sponsors: Synthego, BrainXell Inc.
Partner: Scientist.com
Advertisement
Latest News & Resources
The Sweet Truth: Unwrapping the Science of Semaglutide
August 9, 2023
Taurine: An Unexpected Anti-Aging Ally
July 18, 2023
Content Categories
Aging
Analytical Sciences
Animal Behavioral Neuroscience
Auditory Sciences
Cancer & Oncology Research
Cardiovascular
Cell & Molecular Biology
Clinical Research
Drug Discovery & Development
Education & Teaching
Epidemiology & Infectious Disease
General Biology
Genetics & Genomics
Human Physiology
Industry & Career
Lab Animal Sciences
Materials Science
Metabolic Function
Microbiology & Immunology
Microscopy
Muscle Physiology & Function
Neuroscience
Obesity
Pharmacology
Preclinical Imaging
Renal Physiology
Respiratory Science
Sports Science
Toxicology
Value, Evidence, Access
Vascular Biology
Vision Research